Generic Name
Brinzolamide
Brand Names
Simbrinza, Azopt
FDA approval date: April 30, 1998
Classification: Carbonic Anhydrase Inhibitor
Form: Suspension
What is Simbrinza (Brinzolamide)?
AZOPT is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. AZOPT is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Efficacy and Tolerability of Simbrinza and Rocklatan vs. Cosopt
Summary: A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.